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Abstract
Introduction: Insulin and the insulin-like growth factor (IGF) 
family play a key role in breast cancer (BC). Objective: In this 
study, we evaluated on a genomic scale the potential prog-
nostic value of insulin signaling in early BC. Methods: Candi-
date genes were selected from the published literature and 
gene expression profiling experiments. Three publicly avail-
able BC datasets, containing gene expression data on 502 
cases, were used to test the prognostic ability of the score. 
The gene signature was developed on GSE1456, containing 
microarray data from 159 patients, split into a training set 
(102 breast tumors) and a validation set (n = 57). GSE3494 
and GSE2990 (350 patients) were used for external valida-
tion. Univariate Mann-Whitney test was used to identify 
genes differentially expressed between relapsed and non-
relapsed patients. Expression of genes significantly correlat-
ed with relapse was combined in a linear score. Patients were 
classified as low or high risk with respect to the median val-
ue. Results: On the training set, 15 genes turned out to be 
differentially expressed: 8-year disease-free survival (DFS) 
was 51 and 91% in the high- and low-risk group (p < 0.001), 
respectively. In the validation set, DFS was 97 and 54% (p = 
0.009), respectively. External validation: 8-year DFS was 72 
and 61%, respectively, in GSE3494 (p = 0.03) and 74 and 55% 
in GSE2990 (p = 0.03). By multivariate analyses, the insulin 
signature was significantly associated with DFS, indepen-
dently of age, hormone receptor status, nodal status, and 
grade. Conclusions: Our findings indicate that the insulin 
pathway is involved in BC prognosis at a genomic level and 
provide a window of selectivity for preventive and treatment 
strategies targeting the insulin/IGF pathway in BC patients.
© 2020 S. Karger AG, Basel
Background
In the past 20 years, a substantial body of evidence has 
developed regarding the role of insulin and the insulin-
like growth factor (IGF) family in breast cancer (BC) [1]. 
This research, mainly focused on the IGF system, led to 
the development of antibodies targeting the IGF-1 recep-
tor which have been tested in clinical trials, in many types 
of cancer, with inconsistent results so far [2]. 
Along with the metabolic effects of insulin on glucose 
balance [3], insulin has also been shown to induce cancer 
cell proliferation. The pathways downstream of the insu-
lin/IGF system are well defined: IGF-I and insulin acti-
vate the tyrosine kinase growth receptor pathway, that is, 
the insulin, IGF-I, and hybrid IGF-I/insulin receptors, all 
of which are overexpressed in BC cells [4]. Activation of 
these receptors results in upregulation of the insulin re-









































tion of the MAPKinase and PI3K-Akt pathways [5]. 
Moreover, insulin may also modulate circulating levels of 
IGFs and their binding proteins. Epidemiological obser-
vations have provided evidence that higher circulating in-
sulin levels are associated with an adverse outcome in ear-
ly BC patients [6, 7]. These data suggest that the insulin 
pathway itself plays a major role in BC prognosis and may 
represent a therapeutic target, especially in those patients 
exposed to high plasmatic levels. Hyperinsulinemia gen-
erally reflects the presence of insulin resistance, a syn-
drome characterized by decreased insulin sensitivity in 
peripheral target tissues, such as muscle and fat, which 
includes abnormal laboratory findings, such as glucose 
intolerance, impaired lipid metabolism, and signs of a 
chronic inflammatory state, and manifests as obesity, hy-
pertension, and diabetes [8, 9]. In nondiabetic women 
with early BC it has been observed that hyperinsulinemia 
is associated with the presence of insulin resistance [10]. 
In an attempt to clarify the role of insulin in cancer 
outcome, we hypothesized that it might exert its influence 
on tumor aggressiveness by modulating gene expression 
of BC cells. With these premises, the aim of this study was 
to evaluate the prognostic role of genes related to the in-
sulin and the IGF pathways in early BC by using publicly 
available gene datasets. 
Methods
Gene Selection
Candidate genes were selected from the published literature, 
genomic databases, pathway analysis, and from gene expression 
profiling experiments performed in peripheral tissues of healthy 
subjects screened for insulin resistance by the euglycemic insulin 
clamp technique. In particular, this gene set was identified by mi-
croarray profiling (Affymetrix, Santa Clara, CA, USA) on skeletal 
muscle biopsies of nondiabetic insulin-sensitive and insulin-resis-
tant Pima Indians [11, 12]. These genes can be functionally catego-
rized into various classes including cell growth, signal transduc-
tion, ion transport, transcriptional regulation, protein metabo-
lism, structural genes for the cytoskeleton, lipid and carbohydrate 
metabolism, and chronic inflammation. Data are deposited in 
NCBI Gene Expression Omnibus (GEO; available at http://www.
ncbi.nlm.nih.gov/geo/, GEO Series accession number GSE2508). 
In addition, due to the well-known interactions between the insu-
lin and the IGF pathways in cancer cells, genes related to the IGF 
pathway were selected on Gene Ontology. The panel of selected 
genes and major pathways is shown in Table 1. 
Microarray Datasets
We used 3 publicly available BC datasets, GSE1456 [13], 
GSE3494 [14], and GSE2990 [15], including gene expression data 
on a total of 590 cases with clinical follow-up. The 3 datasets, con-
taining raw intensity data of Affymetrix HU133A arrays, were 
downloaded and pre-processed using R/Bioconductor (GCRMA 
package, quantile normalization, median polish summarization 
[16]). The 3 datasets were pre-processed together using the super-
computer Michelangelo (www.litbio.org). Since the original data-
sets were found to contain in part the same patients, 88 samples 
present in GSE3494 and in GSE2990 were removed from the latter. 
This procedure resulted in a total of 502 cases suitable for the pres-
ent study. Table 2 describes the characteristics of the 3 datasets.
Statistical Methods
The insulin gene signature was developed on GSE1456. The 
dataset was split by a random procedure into a training and a val-
idation set (ratio 2: 1). The signature was developed on the training 
set. Once the signature had been fully specified, the validation set 
was accessed once and only for estimating the prediction accuracy 
of the identified genes. The prognostic value of the signature was 
tested on the validation set by Kaplan-Meier survival analysis and 
Cox regression analysis. A multivariate Cox model was run on the 
whole dataset adjusting for molecular subtype. An external valida-
tion was performed on GSE3494, containing 249 early BC patients, 
and on GSE2990, containing 101 patients, by Kaplan-Meier sur-
vival analysis and Cox regression analysis on both datasets 
(GSE3494 and GSE2990). A stratified multivariate Cox model was 
run on the merged GSE3494/GSE2990 dataset adjusting for age, 
tumor size, nodal status, hormone receptor status, and tumor 
grade. The final model was obtained by means of a background 
procedure based on the likelihood ratio test. To verify the indepen-
dence of insulin/IGF signature, we performed a comparison with 
the 21-Recurrence Score, a clinically validated assay, based on ex-
pression of 21 genes in women with ER+, lymph node-negative BC 
treated with adjuvant tamoxifen [17].
Insulin Gene Signature Development
A univariate Cox regression analysis was run to select genes 
whose expression levels were significantly correlated with disease-
free survival (DFS). When multiple probes were mapped on the 
Table 1. Genes related to the insulin and the insulin growth factor 
pathway evaluated in this study
Insulin pathway Insulin, insulin-induced genes, insulin-de-
grading enzyme (IDE)
Insulin receptor
Insulin receptor substrate (IR-S1,
IR-S2, IR-S4)
Similar to IR-S-like protein
Insulin-like factors 




Solute carrier family 2: GLUT1, GLUT4
Hydroxysteroid (11-β) dehydrogenase 1
CD68 antigen (macrophage marker)
Inflammation IL-6 (interferon, β2)
IL-6 signal transducer
IL-6 receptor 
TNF superfamily, member 2 
IGF pathway IGF 1 (somatomedin C)
IGF 2 (somatomedin A)





IGF 2 antisense 
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same gene ID, the most correlated one by univariate analysis was 
chosen. Those genes related to DFS with a significance level < 0.05 
were included in a multivariate Cox regression model. Their ex-




where wi are weights determined by the coefficients of the mul-
tivariate Cox regression model and valuei are the gene expression 
levels. The median value of the score was chosen as the cutoff to 
classify patients at low or high risk of disease relapse.
Results
One hundred forty-three probe sets were identified on 
the Affymetrix chip, corresponding to 85 insulin-related 
genes. The genes were tested on the GSE1456 dataset. 
This dataset contains raw data from 159 early BC patients 
with a median follow-up of 6.1 years. The dataset was split 
by a random procedure into a training set and a validation 
set of 102 and 57 primary breast tumors, respectively. On 
the training set, 15 genes turned out to be differentially 
expressed between relapsed and nonrelapsed patients 
with a significance level < 0.05. The insulin signature con-
Table 2. Characteristics of the gene expression datasets included in this study
Dataset GEO: GSE1456 GEO: GSE3494 GEO: GSE2990
Patients, n 159 249 101







Mean age, years 58 62 58
Mean tumor size, mm 22 22 22
Tumor size <21 mm, % 62 51 58
Grade 3, n (%) 65 (41) 196 (78) 31 (31)
ER positive, n (%) 130 (82) 222 (89) 85 (84)
Positive lymph nodes, n (%) 60 (38) 77 (31) 15 (15)
Adjuvant HT, n (%) 114 (72) 67 (27) 0
Adjuvant chemotherapy, n (%) 30 (19) 60 (24) 0
Mean follow-up, years 6.2 7.1 7.0
Proportion relapsed, % 25 36 40
Platform Affymetrix Affymetrix Affymetrix
HT, hormone therapy.
Table 3. List of the 15 genes of the insulin gene score
Probe set ID Gene symbol Low risk High risk p value Score 

































































































































































sists of a score, defined as the linear combination of the 
15 genes with the standardized Cox’s regression coeffi-
cient as the weight (Table 3). The median value of the 
score was used to classify patients as high and low risk. 
The 15 genes can be functionally divided into 3 classes: 
those belonging to the insulin pathway (4 genes, 27%), the 
chronic inflammation pathway (5 genes, 30%), and the 
IGF pathway (6 genes, 40%). Individual hazard ratios 
(HRs) related to the overexpression of each of the 15 genes 
are presented in Figure 1. In the training set (102 patients), 
the 8-year DFS was 91% (standard error [SE] 4%) in the 
low-risk group and 51% (SE 8%) in the high-risk group 
Fig. 1. Individual HRs related to the over-
expression of the 15 genes.





































Insulin-Related Genes and Breast Cancer 5Breast Care
DOI: 10.1159/000509207
(p < 0.001). Univariate DFS HR (high vs. low risk) was 10.6 
(95% CI 3.2–35.5, p < 0.0001). The gene signature was 
then tested on the 57 patients included in the validation 
set. The 8-year DFS was 97% (SE 3%) and 54% (SE 10%) 
in the low-risk and the high-risk group (p = 0.03), respec-
tively, supporting the discriminating ability of the identi-
fied insulin sensitivity score. Univariate DFS HR was 4.6 
(95% CI 1.01–20.7, p = 0.04). Figure 2 shows Kaplan-Mei-
er survival curves according to the high- and low-risk 
group in the training and validation set.
The identified insulin signature was then tested on 2 
external independent datasets, GSE3494 including 249 
early BC patients and GSE2990 including 101 early BC 
patients. The score significantly predicted DFS in both 
datasets: in GSE3494, the 8-year DFS was 72% (SE 5%) in 
the low-risk group and 61% (SE 4%) in the high-risk 
group (p = 0.04). By univariate analysis, the DFS HR was 
1.6 (95% CI 1.1–2.5, p = 0.03). In GSE2990, the 8-year 
DFS was 74% (SE 7%) and 55% (SE 8%) in the low-risk 
and the high-risk group, respectively (p = 0.008). By uni-
variate analysis, the DFS HR was 2.3 (95% CI 1.1–4.6, p = 
0.02). Kaplan-Meier survival curves obtained in the 2 in-
dependent datasets are shown in Figure 3. 
By multivariate analysis of the merged datasets 
(GSE3494 and GSE2990), the insulin signature turned 
out to be significantly associated with DFS (HR 1.5, 95% 
CI 1.0–2.3, p = 0.04), independently of other established 
prognostic factors, including age, ER status, nodal status 
and grade, except for tumor size (Table 4).
Three hundred fifty-seven patients (249 from GSE3494 
and 108 from GSE2990) were assessable for type of adju-
vant therapy. Of these, 130 (30%) received endocrine 
therapy and 41 (9%) received chemotherapy according to 
local clinical practice. The test for interaction between 
type of adjuvant systemic therapy (yes or no) and the in-
sulin signature was statistically significant (p = 0.009). In 
patients who received adjuvant systemic therapy, either 
endocrine therapy or chemotherapy, the insulin signa-
ture identified a subset of patients with high risk of re-
lapse despite treatment (HR 2.77, 95% 1.59–4.82, p < 
0.0001).
Finally, we performed a comparison of the insulin 
score with the 21-Recurrence Score (21-gene signature) 
in the validation set (57 patients); a positive correlation 
between 2 signatures was observed (r = 0.34, p < 0.05; Fig-
Fig. 3. Kaplan-Meier curves of DFS in the 2 datasets used for external validation. DFS, disease-free survival; 15-
IS, 15-Insulin Sensitivity.
Table 4. Multivariate Cox analysis of GSE3494 and GSE2990 
merged dataset (350 patients)









































































ure 4a). When using the median value of the score to clas-
sify patients as high and low risk in a multivariate Cox 
analysis, HR (high vs. low risk) for DFS was 1.83 (95% CI 
1.07–3.15, p = 0.03) for 15-Insulin Sensitivity signature, 
while it was 1.02 (95% CI 1.00–1.04, p = 0.03) in 21-Re-
currence Score. This observation supports the discrimi-
nating ability of the identified insulin sensitivity score 
and its independence from the 21-Recurrence Score 
(Fig. 4b).
Discussion
In this study, we used a mechanism-driven approach 
to evaluate the involvement of insulin signaling in BC 
prognosis on a genomic scale. In particular, we identified 
a gene signature based on the differential expression of 15 
genes related to the insulin pathway that was strongly as-
sociated with DFS in early BC. The ability of the insulin 
signature to predict outcome was maintained after exter-
nal validation performed on 2 different large independent 
datasets. In Cox’s multivariate analyses, the insulin gene 
signature was found to be an independent variable in pre-
dicting DFS when molecular subtype and other estab-
lished factors, such as nodal status, histologic grade, hor-
mone receptor status, and age, were taken into account. 
The genes included in the insulin signature showed no 
overlap with other prognostic classifiers, with the excep-
tion of the IGF1 gene, shared with the prognostic signa-
ture developed by Pawitan et al. [13]. However, this last 
observation, due to the nature of this analysis, has to be 
considered as exploratory, since no selection of ER-posi-
tive samples was done.
The 15 genes can be functionally divided into 3 classes: 
those belonging to the insulin pathway (27%), the chron-
ic inflammation pathway (30%), and the IGF pathway 
(40%). The insulin pathway is present with 4 genes: IN-
SIG1, IDE, IRS1, and IRS2. Preclinical evidence indicates 
Fig. 4. Scatter plot (A) and Kaplan-Meier curves (B) of DFS in comparison with 15-IS gene and 21-RS signatures. 
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that INSIG1 (insulin-induced gene 1) is involved in regu-
lation of transcription and is upregulated by exposure to 
genotoxic agents in cancer models [18]; IDE (insulin-de-
grading enzyme) is a zinc metalloprotease involved in in-
tracellular degradation of insulin recently detected in ma-
lignant tissues, including BC [19]. IRS1 and IRS2 (insulin 
receptor substrate 1 and 2) are major substrates for the 
insulin and the IGF receptors and they mediate signals to 
promote tumor cell survival, growth, and motility in BC 
cells [20]. Five genes (IL-6, TNFR10b, TNFR12a, TNFR21, 
and TNF10), pertinent to the chronic inflammation path-
way, turned out to be differentially expressed between re-
lapsed and nonrelapsed patients; among these, IL-6 (in-
terleukin-6) and TNF (tumor necrosis factor) are multi-
functional cytokines produced by a number of tumor 
cells, including BC [21, 22], and are correlated with an 
adverse prognosis in advanced BC stages [23]. 
In the IGF-related group, high expression of the IGF1 
gene was associated with the low risk profile. These data 
are consistent with available evidence indicating that at a 
cellular level, high IGF1 expression is correlated with a 
more favorable outcome in BC patients. Among the oth-
er IGF-related genes, IGF-binding protein genes, namely 
IGFBP4, IGFBP6, and IGFBP7, were also overexpressed 
in the low-risk profile. IGFBP4 has been shown to be an 
independent prognostic factor in BC and a predictor of 
endocrine responsiveness [24]. Finally, both up- and 
downregulation of IGFBP7 have been reported in BC [25] 
and are involved in modulating VEGF expression and 
signaling as well [26]. 
These data suggest that insulin signaling may be a key 
regulatory pathway in BC and may represent a therapeu-
tic target. The implementation of therapies that target hy-
perinsulinemia is one of the most intriguing and emerg-
ing fields of research in different types of tumors. In ad-
dition to lifestyle interventions that are effective in 
reducing insulin levels in BC survivors [27], but strongly 
dependent on patient attitude and compliance, interest 
has focused on metformin, an anti-diabetic drug widely 
prescribed for the treatment of hyperglycemia and hyper-
insulinemia. Cheap and generally well tolerated [28], 
meftormin has also been shown to retain antiproliferative 
properties, through the activation of the AMPK pathway, 
in preclinical BC models [29]. Epidemiologic evidence 
also indicated that in diabetic patients, metformin is as-
sociated with reduced risk of cancer incidence and mor-
tality [30]. Moreover, in a series of 2,529 BC patients re-
ceiving preoperative chemotherapy at MD Anderson 
Cancer Center, the probability of achieving a pathological 
complete response was reported to be 30% higher in dia-
betic patients receiving metformin as compared to non-
diabetic patients [31]. 
In the past few years, these data prompted the exploi-
tation of metformin as an anticancer drug in BC, with 
inconsistent results. Our group performed 2 randomized 
clinical trials in early and advanced BC patients. In the 
first one, 200 nondiabetic patients with operable BC were 
randomized to receive metformin or placebo in a win-
dow-of-opportunity, preoperative study. The primary 
endpoint was tumor proliferation. Overall, metformin 
did not significantly impact Ki-67; however, a significant 
difference was detected according to the level of insulin 
sensitivity [32].
In the MYME study [33], 122 nondiabetic women with 
HER2-negative metastatic breast cancer were random-
ized to receive first-line chemotherapy plus metformin or 
chemotherapy alone; the final results failed to provide ev-
idence of an additional benefit of metformin in terms of 
progression-free and overall survival. Noteworthy, a sig-
nificantly worse outcome was observed in insulin-resis-
tant patients (HOMA ≥2.59, independent of metformin 
administration). A biological collateral study, Trans-
MYME, evaluated in the same patients the prognostic 
role of IGF-1R expression on circulating tumor cells, in-
dicating that loss of IGF-1R expression was associated 
with a significantly worse outcome [34]. Yet, a possible 
limitation of this study was the absence of any informa-
tion related to individual patient metabolic status, includ-
ing body mass index, level of insulin sensitivity, and nu-
tritional status. 
In conclusion, our study suggests that it is possible to 
identify a subset of BC patients whose prognosis is strong-
ly modulated by a set of genes related to the insulin path-
way. This might help to better individualize lifestyle and 
therapeutic interventions targeting insulin signaling, by 
selecting those patients at high risk of relapse according 
to the insulin signature and to evaluate the prognostic 
impact of epigenetic modulations induced by these types 
of interventions. 
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